BUFFALO, NY - In August, 142 startups were announced as semifinalists of the 43 North competition. The $5 million startup competition offers a grand prize of $1 million and various secondary prizes.
At the time of the announcement, 25 WNY-based startups were named as semifinalists. The judges of competition have narrowed the finalists down to 16, including one Buffalo-based startup.
Abcombi Biosciences Inc. is a biotech company aiming to safely, effectively producing vaccines and therapeutics on a local level. The company claims their platform can be customized and applied to any disease treatable by a shot. Different than traditional vaccinations, Abcombi claims to have developed a "smart vaccine."
In addition to being named a finalist in the 2016 43 North competition, Abcombi Biosciences won the grand prize in the Bright Buffalo Niagara forum.
Interestingly, seven Boston-based startups were selected as semifinalists and four moved on to the final round of the competition.
The 43 North winners will be announced at an event on October 29th. Part of the requirement for 43 North winners is the startup must operation in Buffalo for one year.
Other finalists include: Andromium (San Francisco, CA), Arthena (NYC), Asarasi (Katonah, NY), Bounce Imaging (Boston, MA), CleanCapital (Washington, D.C.), Formarum (Toronto, Ontario, Canada), HigherMe (Boston, MA), MobioSense (Taipei, Taiwan), NeoReach (San Francisco, MA), Oncolinx (Boston, MA), PathoVax (Baltimore, MD), Strawberry Energy (Belgrade, Serbia), The Wealth Factory (Washington, D.C.), UltraCell Insulation (Boston, MA), WeDidIt (Brooklyn).
